Regeneron Pharmaceuticals Inc.

REGN

Held by 3 specialist biotech funds

High Convergence

3 funds opened new positions. Next phase2 readout (Intravitreal Aflibercept Injection): Dec 2009. Short interest: 3.3% of float.

BiotechnologyCEO: Leonard S. SchleiferIPO: 1991Website ↗

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Catalysts

Phase 2PositiveQ4 2009Intravitreal Aflibercept InjectionDiabetic Macular EdemaNCT00789477

Primary: Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF) (At week 24)Enrollment:221/221Sites: 47RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ2 2010REGN475SciaticaNCT00991172

Primary: Sciatic pain between baseline and end of week 4 (4 weeks)Enrollment:159/159Sites: 30RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ1 2011REGN475/SAR164877Abdominal Pain UpperNCT01001923

Primary: Mean change from baseline in pain intensity as assessed by Pain Intensity Numeric Rating Scale (PI-NRS) (baseline and 4 weeks after injection)Enrollment:15/15Sites: 17RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ3 2016DupilumabAtopic DermatitisNCT02395133

Primary: Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769) (Baseline (Parent Study), Baseline (Current Study) and Week 36 (Current study))Enrollment:422/422RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ4 2019FasinumabOsteoarthritis, Knee, Osteoarthritis, HipNCT03304379

Primary: Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Scores up to Week 24 in Participants Treated With Fasinumab Compared to Placebo (Baseline up to Week 24)Enrollment:1,650/1,650Sites: 71RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ1 2020REGN3500Atopic DermatitisNCT03738423

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16 (Week 16)Enrollment:129/129Sites: 89RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ2 2020EvinacumabHypercholesterolemiaNCT03175367

Primary: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) (Baseline and Week 16)Enrollment:272/272Sites: 95RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ3 2021REGN2810/ipiNon-small Cell Lung CancerNCT03515629

Primary: Progression-Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessments (Up to 32 months)Enrollment:5/5Sites: 3RANDOMIZED, TREATMENT

Phase 2Q3 2023Pexastimogene Devacirepvec (Pexa-Vec)Renal Cell CarcinomaNCT03294083

Phase 2NegativeQ4 2023REGN4461Familial Partial Lipodystrophy, Metabolic AbnormalitiesNCT05088460

Phase 2NegativeQ1 2024CMP-001Squamous Cell Carcinoma of Head and NeckNCT04633278

Phase 2Q1 2025cemiplimabNon-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell CarcinomaNCT03916627

Phase 2Q2 2025VV1Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal CancerNCT04291105

Phase 3Jul 8, 2025Pozelimab + CemdisiranGeneralized Myasthenia GravisNCT05070858

Phase 3Jul 17, 2025GaretosmabFibrodysplasia Ossificans ProgressivaNCT05394116

Phase 3Q3 2025Aflibercept 8 mgNeovascular Age-Related Macular Degeneration, Diabetic Macular EdemaNCT06491914

Phase 2Sep 16, 2025Non-small Cell Lung Cancer (NSCLC)NCT05553834

Phase 2Q3 2025CemiplimabCutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell CarcinomaNCT04050436

Phase 2NegativeQ4 2025REGN5381Uncontrolled HypertensionNCT06833190

Phase 2Q4 2025CemiplimabMetastatic Solid TumorNCT04706715

Phase 2Dec 15, 2025TirzepatideObesityNCT06373146

Phase 3Dec 29, 20258 mg aflibercept (BAY 86-5321) (High Dose)Diabetic Macular EdemaNCT06422507

Phase 2Dec 31, 2025Aspirin ChallengeAspirin-exacerbated Respiratory DiseaseNCT05031455

Phase 2Jan 31, 2026DupilumabPruritisNCT06226610

Phase 2Q1 2026UbamatamabRecurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal CancerNCT03564340

Phase 2Q1 2026REGN7544Sepsis-Induced HypotensionNCT06608901

Phase 2Feb 18, 2026DupilumabEosinophilic Gastritis (Eo G), Eosinophilic Duodenitis (Eo D), Eosinophilic Gastrointestinal Disease (EGID)NCT05831176

Phase 3Mar 16, 2026FianlimabMelanomaNCT05352672

Phase 2Mar 20, 2026REGN7544Postural Orthostatic Tachycardia Syndrome (POTS)NCT06593600

Phase 2Apr 1, 2026Sarilumab SAR153191 (REGN88)Juvenile Idiopathic ArthritisNCT02991469

Phase 2Q2 2026FianlimabResectable Non-small Cell Lung CancerNCT06161441

Phase 2Apr 30, 2026CemiplimabColon CancerNCT05961709

Primary: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 (Through study completion; an average of 1 year)Enrollment:50/50Sites: 5NA, TREATMENT

Phase 2May 15, 2026DupilumabColitis UlcerativeNCT05731128

Phase 2Q2 2026Trevogrumab-Part AObesityNCT06299098

Primary: Incidence of treatment-emergent adverse events (TEAEs) (Baseline to week 7)Enrollment:1,005/1,005Sites: 60RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Jun 1, 2026REGN9933Venous ThromboembolismNCT06299111

Phase 3Jun 8, 2026DupilumabLichen Simplex ChronicusNCT06687967

Phase 3Jun 8, 2026DupilumabLichen Simplex ChronicusNCT06687980

Phase 2Q3 2026OdronextamabB-cell Non-Hodgkin Lymphoma (B-NHL)NCT03888105

Phase 3Q3 2026mibavademabGeneralized LipodystrophyNCT06548100

Phase 2Aug 7, 2026Itepekimab (SAR440340)Chronic Rhinosinusitis Without Nasal PolypsNCT06691113

Phase 2Q3 2026REGN7075Advanced Solid TumorsNCT04626635

Phase 3Q4 2026DupilumabAtopic DermatitisNCT02612454

Phase 3Q4 2026RavulizumabParoxysmal Nocturnal HemoglobinuriaNCT05133531

Phase 2Q4 2026AlirocumabHypercholesterolemiaNCT07477704

Phase 2Q4 2026cemiplimabMelanomaNCT06190951

Phase 2Nov 13, 2026OlatorepatideOverweight or ObesityNCT07431086

Phase 2Q4 2026REGN2810Prostate Cancer MetastaticNCT03951831

Phase 2Q4 2026DupilumabAsthma, AllergicNCT05720325

Phase 3Dec 1, 2026Itepekimab (SAR440340)Chronic Obstructive Pulmonary DiseaseNCT06208306

Phase 2Q4 2026DegarelixProstate CancerNCT04989946

Phase 2Q4 2026CemiplimabCarcinoma, Non-Small-Cell LungNCT06623656

Phase 2Dec 31, 2026DupilumabAsthmaNCT05347771

Phase 2Jan 2, 2027OdronextamabFollicular Lymphoma, LymphomaNCT07128641

Phase 3Jan 8, 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT06834360

Phase 3Jan 8, 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT06834347

Phase 2Q1 2027REGN4336Metastatic Castration-resistant Prostate CancerNCT05125016

Phase 2Q1 2027REGN7508Atrial Fibrillation (AF)NCT07175428

Phase 3Q1 2027REGN7508Venous Thromboembolism (VTE)NCT07015905

Phase 3Feb 28, 2027REGN5713Allergic ConjunctivitisNCT07309432

Primary: Ocular itch score in participants receiving REGN5713-5715 compared to placebo (At Day 8 post-Conjunctival Allergen Challenge (CAC))Enrollment:Target 350Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Mar 22, 2027fianlimabMelanomaNCT06246916

Phase 2Mar 25, 2027REGN5668Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CancerNCT04590326

Phase 2Q2 2027S095018Non-small Cell Lung Cancer (NSCLC)NCT06162572

Phase 3Q2 2027OdronextamabB-Cell Non-Hodgkin Lymphoma (B-NHL)NCT06230224

Primary: Event-free survival (EFS) as assessed by independent central review (ICR) (Assessed up to 3 years)Enrollment:Target 216Sites: 101RANDOMIZED, TREATMENT

Phase 2May 15, 2027CemiplimabLocally Recurrent Oral Cavity Squamous Cell CarcinomaNCT06448026

Phase 2Q2 2027ALN-CIDEBMetabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated SteatohepatitisNCT06836609

Phase 3Q2 2027REGN7508Symptomatic Venous Thromboembolism (VTE)NCT07213778

Phase 2Q2 2027CemiplimabNon-Small Cell Lung CancerNCT06465329

Phase 3Q2 2027MibavademabMonogenic ObesityNCT07220772

Phase 2Q2 2027SNS-101 (anti-VISTA)Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck CancerNCT05864144

Phase 2Jun 30, 2027CemiplimabHPV-Related Squamous Cell CarcinomaNCT04988074

Phase 3Q3 2027nexiguran ziclumeranNeuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative DiseaseNCT06672237

Primary: Modified Neuropathy Impairment Score +7 (mNIS+7) (18 Months)Enrollment:Target 60Sites: 14RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2027MibavademabFunctional Hypothalamic Amenorrhea (FHA)NCT07235917

Primary: Change from the highest serum estradiol observed during a 28-day period (Baseline to month 6)Enrollment:Target 34Sites: 5RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Aug 31, 2027LinvoseltamabMultiple MyelomaNCT06376526

Phase 2Q3 2027ErveboEbola Virus DiseaseNCT05202288

Phase 2Q3 2027CemiplimabNSCLC, Locally AdvancedNCT06865339

Phase 2Q3 2027ALN-ANG3Diabetic Kidney Disease (DKD)NCT07271186

Phase 2Q3 2027FianlimabAdvanced MelanomaNCT06594991

Phase 3Oct 20, 2027Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT07484230

Phase 3Oct 28, 2027DupilumabPrurigo NodularisNCT06293053

Phase 2Nov 3, 2027DupilumabAlopecia AreataNCT05551793

Phase 2Nov 15, 2027REGN5678Metastatic Castration-Resistant Prostate Cancer (m CRPC), Clear Cell Renal Cell Carcinoma (cc RCC)NCT03972657

Phase 2Q4 2027VonsetamigChronic Kidney Disease (CKD)NCT05092347

Primary: Incidence of adverse event(s) of interest (AEI) from the first dose through end of the safety observation period (Up to approximately 6 weeks)Enrollment:Target 56Sites: 10NA, TREATMENT

Phase 3Nov 29, 2027PozelimabAge-related Macular Degeneration (AMD), Geographic Atrophy (GA)NCT06541704

Phase 2Dec 1, 2027CemiplimabLung Cancer (NSCLC)NCT07450183

Phase 3Q4 2027NTLA-2001Transthyretin Amyloidosis (ATTR) With CardiomyopathyNCT06128629

Phase 2Q4 2027Cemiplimab-RwlcNon-small Cell Lung Cancer Stage IIINCT06449313

Phase 3Dec 31, 2027CemiplimabRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8NCT06616584

Phase 3Q1 2028CemiplimabCutaneous Squamous Cell CarcinomaNCT03969004

Phase 2Q1 2028REGN7999Non-Transfusion Dependent Beta-Thalassemia (NTDT)NCT06421636

Phase 2Jan 26, 2028BNT116Advanced Non-Small Cell Lung CancerNCT05557591

Phase 2Q1 2028CemiplimabColon and Rectal CancerNCT07433673

Phase 2Q1 2028Encorafenib + BinimetinibMelanoma BRAF V600E/K Mutated, Melanoma and Brain MetastasesNCT06887088

Phase 3Feb 7, 2028OdronextamabFollicular Lymphoma (FL)NCT06091254

Phase 2Q1 2028REGN13335Pulmonary Arterial Hypertension (PAH)NCT07318597

Phase 3Q1 2028OdronextamabDiffuse Large B-cell Lymphoma (DLBCL)NCT06091865

Phase 2Q1 2028CemiplimabBladder Urothelial CarcinomaNCT07414992

Phase 2Q1 2028CemiplimabHead and Neck Squamous Cell CarcinomaNCT06855212

Phase 2Apr 10, 2028OdronextamabRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular LymphomaNCT06784726

Phase 2Q2 2028ALN-HSDMetabolic Dysfunction-Associated Steato Hepatitis (MASH)NCT05519475

Phase 2Q2 2028Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]Colon CancerNCT07224022

Phase 3Q2 2028FianlimabMelanomaNCT05608291

Phase 3Q2 2028MibavademabGeneralized LipodystrophyNCT07220785

Phase 2Q2 2028CemiplimabPleural MesotheliomasNCT07234058

Phase 2Q2 2028CemiplimabColorectal CancerNCT06205836

Phase 2Jun 1, 2028CemiplimabColo-rectal CancerNCT07058012

Phase 2Q2 2028FDC fianlimab+cemiplimabHead and Neck Squamous Cell Carcinoma (HNSCC)NCT06769698

Phase 3Q2 2028dupilumabEosinophilic Esophagitis (Eo E)NCT07112378

Phase 2Jun 28, 2028REGN7041Active Noninfectious Uveitis Affecting the Posterior SegmentNCT07218770

Phase 2Jun 30, 2028LinvoseltamabRecurrent Multiple Myeloma, Refractory Multiple MyelomaNCT07181941

Phase 2Q2 2028MotixafortidePancreatic Cancer, Adenocarcinoma of the Pancreas, AdenocarcinomaNCT04543071

Phase 2Jul 31, 2028UbamatamabSMARCB1-Deficient MalignanciesNCT06444880

Phase 2Q3 2028Cemiplimab Plus GemcitabinePancreatic Ductal Adenocarcinoma (m PDAC)NCT06790602

Phase 2Q3 2028LinvoseltamabRelapsed/Refractory Systemic Light Chain AmyloidosisNCT06292780

Phase 2Sep 1, 2028SAR444881Solid TumorsNCT06651593

Phase 2Q4 2028CemiplimabBasal Cell Carcinoma (BCC), First Line TreatmentNCT06981325

Phase 2Dec 7, 2028UbamatamabOvarian CancerNCT06787612

Phase 3Q4 2028garetosmabFibrodysplasia Ossificans Progressiva (FOP)NCT07559513

Phase 3Dec 12, 2028Itepekimab (SAR440340)Chronic Rhinosinusitis With Nasal PolypsNCT07424144

Phase 3Dec 21, 2028DupilumabWheezing, AsthmaNCT06191315

Phase 2Q4 2028cemiplimabCutaneous Basal Cell CarcinomaNCT07251413

Phase 2Q4 2028GemcitabineBladder Cancer, Muscle-Invasive Bladder CarcinomaNCT06571708

Phase 3Q1 2029OdronextamabRelapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)NCT06149286

Phase 3Q1 2029Dupilumab Prefilled SyringeAsthma ControlNCT07309614

Phase 3Q1 2029PozelimabParoxysmal Nocturnal HemoglobinuriaNCT05744921

Phase 3Mar 28, 2029REGN7508Atrial Fibrillation (AF)NCT07430956

Phase 3Q1 2029CemiplimabNon-Small Cell Lung CancerNCT06931717

Phase 3Q2 2029REGN7508Peripheral Artery Disease (PAD)NCT07318610

Phase 2Q2 2029CemiplimabCutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, NeoplasmsNCT05878288

Phase 3Jun 15, 2029LinvoseltamabRelapsed and/or Refractory Multiple Myeloma (RRMM)NCT07222761

Phase 3Q3 2029OdronextamabFollicular Lymphoma (FL)NCT06097364

Phase 2Q3 2029Cemiplimab 350 MG Intravenous SolutionClear Cell Renal Cell CarcinomaNCT07223541

Phase 2Q4 2029Fianlimab+cemiplimabMelanomaNCT06848088

Phase 3Q4 2029PozelimabParoxysmal Nocturnal HemoglobinuriaNCT07154745

Phase 2Nov 29, 2029ALN-CFBParoxysmal Nocturnal Hemoglobinuria (PNH), Persistent AnemiaNCT07187401

Phase 2Q4 2029FianlimabAdvanced Renal Cell Carcinoma (a RCC), Metastatic Renal Cell Carcinoma ( m RCC), Clear Cell Renal Cell Carcinoma (cc RCC)NCT07188896

Phase 2Dec 31, 2029Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cyclesMerkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant ImmunotherapyNCT07387198

Phase 3Q1 2030fianlimabNon-small Cell Lung CancerNCT05800015

Phase 3Jan 23, 2030REGN7508Cancer-Associated Thrombosis (CAT)NCT07410117

Phase 2Q1 2030REGN10597Melanoma, Clear-Cell Renal-Cell Carcinoma (cc RCC), Advanced Solid TumorsNCT06413680

Phase 3Q1 2030fianlimabAdvanced Non-Small Cell Lung CancerNCT05785767

Phase 2Q2 2030OxaliplatinColorectal CancerNCT07281768

Phase 3May 3, 2030CemiplimabCutaneous Squamous Cell Carcinoma (CSCC)NCT06585410

Phase 2Q2 2030UbamatamabAdvanced/Metastatic Non-Small Cell Lung CancerNCT07154290

Phase 2Q3 2030MaaT033 capsuleNSCLC (Advanced Non-small Cell Lung Cancer)NCT07001618

Phase 2Oct 31, 2030ZIV-AfliberceptMetastatic Uveal MelanomaNCT06121180

Phase 2Q2 2031Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)NCT05788536

Phase 3May 1, 2031OdronextamabB-cell Non Hodgkin LymphomaNCT05991388

Phase 2Jun 5, 2031ALN-SODAmyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) GeneNCT06351592

Primary: Incidence of Treatment-Emergent Adverse Event (TEAEs) in participants treated with ALN-SOD (At week 4 and through week 228)Enrollment:Target 42Sites: 16RANDOMIZED, TREATMENT

Phase 2Jul 5, 2031CemiplimabLocally Advanced Basal Cell Carcinoma, Basal Cell CarcinomaNCT05929664

Phase 3Jul 8, 2031REGN7508Venous Thromboembolism (VTE)NCT07493304

Phase 2Q2 2032REGN5093NSCLCNCT04077099

Phase 2Q2 2032LinvoseltamabMonoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)NCT06140524

Phase 2Q3 2032CemiplimabHigh-Grade Glioma (HGG), Posterior Fossa-A EpendymomaNCT07567469

Phase 2Dec 2, 2032LinvoseltamabMultiple MyelomaNCT06910124

Primary: Minimum Residual Disease Negative Conversion Rate (12 months)Enrollment:Target 32Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q1 2033LinvoseltamabSmoldering Multiple Myeloma (SMM)NCT05955508

Phase 2Mar 30, 2033LinvoseltamabMultiple MyelomaNCT03761108

Phase 3Q2 2033LinvoseltamabRelapsed Refractory Multiple Myeloma (RRMM)NCT05730036

Phase 3Q3 2033LinvoseltamabHigh Risk Smoldering Multiple Myeloma (HR-SMM)NCT07393282

Phase 2Q3 2033LinvoseltamabRelapsed Refractory Multiple Myeloma (RRMM)NCT07455851

Primary: Occurrence of Dose Limiting Toxicities (DLTs) from the first dose of REGN17372 in combination with linvoseltamab (Up to 35 days)Enrollment:Target 150Sites: 2NON_RANDOMIZED, TREATMENT

Phase 2Nov 11, 2033LinvoseltamabRelapsed/Refractory Multiple MyelomaNCT06669247

Phase 2Q3 2034REGV131Hemophilia BNCT06379789

Phase 2Q4 2035LinvoseltamabMultiple MyelomaNCT05828511

Primary: Incidence of Dose-Limiting Toxicities (DLTs) (End of the Observation period; up to day 28)Enrollment:Target 149Sites: 32NON_RANDOMIZED, TREATMENT

Phase 3Q4 2036LinvoseltamabMultiple MyelomaNCT06932562

Phase 3Q2 2038LinvoseltamabMultiple Myeloma (MM)NCT07428369

Phase 2TBDR475Thermal Injury PainNCT01053702

Primary: Change in procedural pain intensity0Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Regeneron Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research